UNSPSC 51112603: Ecomustine

This classification denotes a nitrosourea compound with the molecular formula C10H18ClN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7369R4J7S2, chemically known as methyl 3-(3-(2-chloroethyl)-3-nitrosoureido)-2,3-dideoxy-alpha-d-arabino-hexopyranoside but more generally known as ecomustine, which bears US NIH Compound Identifier 65855. European Medicines Agency schedules Ecomustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06449MIG.

UNSPSC 51112603 Ecomustine is a Commodity code covering pharmaceutical products, specifically a chemotherapy agent used in cancer treatment. State and local governments procure this drug primarily through health and human services departments and Medicaid programs as part of prescription benefit management and direct pharmaceutical procurement initiatives. The scope of work under this code encompasses the supply, distribution, and contracting arrangements for ecomustine itself, as well as the administrative mechanisms through which state agencies and health plans source, manage, and fulfill prescriptions for this oncology medication. Issuing bodies are typically state health agencies, Medicaid offices, and state employee health benefit programs that manage pharmacy benefits for beneficiaries and retirees. The code also extends to vendors supplying ecomustine through various contracting models — traditional pharmacy benefit manager relationships, group purchasing organizations, direct-to-manufacturer arrangements, and self-insured employer or state agency contracts.

The Texas Health and Human Services Commission posted the most recent activity under this code: an RFI (Request for Information) issued April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. This exploratory procurement solicits information from pharmaceutical suppliers and intermediaries regarding their capacity to contract directly with state agencies and self-insured plans outside conventional pharmacy benefit manager and wholesaler channels, with emphasis on negotiated net pricing models, value-based agreements, and fulfillment flexibility. The RFI does not establish budget, timeline, or formal award parameters — it is a preliminary information-gathering phase designed to inform the state's future RFP and contracting strategy. The limited recent activity under this Commodity code suggests that ecomustine procurement in state and local markets remains episodic and concentrated within Medicaid and state employee health programs rather than a broad market segment.